Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. It has a commercial agreement with Neste to Jointly scale newgold winter canola for biofuels production. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
What does it do?
Bayer is a massive German company that makes three very different things: prescription drugs, over-the-counter health products, and farm chemicals. You've probably used their products without knowing it — Aspirin is one of Bayer's most famous brands, and farmers around the world use their pesticides and herbicides to grow crops. On the drug side, they make medicines for heart disease, cancer, and eye conditions. Think of them as a company that touches your medicine cabinet, your doctor's office, and the food on your plate.
Bayer is under enormous pressure right now because of lawsuits tied to Roundup, a weedkiller it inherited when it bought Monsanto in 2018 for $63 billion — a deal many consider one of the worst corporate acquisitions in recent history. The company lost $3.6 billion last year and its stock has fallen roughly 75% from its peak, making it either a deep value opportunity or a value trap depending on who you ask. Resolving its legal liabilities and rebuilding investor trust is the defining question for this company right now.
How does it make money?
Bayer generates about $45.6 billion in annual revenue across three segments. Pharmaceuticals — its largest division — sells prescription drugs like Xarelto (a blood thinner) and Eylea (an eye disease treatment), though Xarelto is losing patent protection, which means cheaper generics are cutting into sales. Consumer Health sells familiar brands like Aspirin, Claritin, and Bepanthen directly to consumers in pharmacies. Crop Science, the division that came with the Monsanto acquisition, sells herbicides like Roundup, seeds, and other agricultural products to farmers globally.
Why do investors care?
Bayer's stock trades at a very low price relative to its sales, which attracts investors who believe the market has overreacted to its problems and the company is genuinely cheap. The bull case rests on Bayer settling its Roundup lawsuits at a manageable cost, stabilizing its pharma pipeline with new drugs to replace Xarelto's lost revenue, and potentially breaking up the company to unlock hidden value. A lot has to go right: legal settlements need to be affordable, new drug trials need to succeed, and management needs to execute a turnaround under serious financial strain.
Deep Dive
MemberA full investor briefing on Bayer Aktiengesellschaft — history, leadership, risks, and outlook.